PolarisQB develops a quantum computing platform that utilizes quantum annealing and quantum-inspired algorithms to optimize drug design by exploring a chemical space significantly larger than traditional methods. This technology enables biotech and pharmaceutical companies to rapidly identify and develop viable drug candidates, reducing discovery timelines from months to days.
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods struggle to efficiently explore the vast chemical space required to identify viable drug candidates, leading to lengthy discovery timelines and limited success in finding optimal molecules for complex protein targets. Conventional screening methods and AI-driven approaches often fail to reach the scale and speed needed for multi-objective optimization.
Solution
PolarisQB offers a quantum-aided drug design (QuADD) platform that leverages quantum annealing and quantum-inspired algorithms to accelerate the identification of drug candidates. The platform explores a significantly larger chemical space than traditional methods, enabling the discovery of novel molecules with enhanced binding affinity and drug-like properties. By applying multi-objective optimization at scale, PolarisQB's technology can identify high-quality lead-like molecules applicable to any protein target without requiring training data. The QuADD platform offers solutions ranging from rapid hit identification to joint development of best-fit molecules, significantly reducing discovery timelines from months to days.
Target Audience
PolarisQB serves pharmaceutical, biotechnology, agriculture, and contract research organizations (CROs) seeking to accelerate drug discovery and identify novel drug candidates for challenging protein targets.
Features
- Quantum annealing and quantum-inspired algorithms for ultra-large scale optimization
- Exploration of chemical spaces exceeding 10^30 molecules, orders of magnitude larger than traditional screening
- Multi-objective optimization for identifying molecules with stronger binding, greater diversity, and improved drug-like properties
- QuADD Rapid: Generates 1-5k top-quality lead-like molecules for target protein binding pockets
- QuADD Select: Delivers 20-200 molecules optimized for target protein within 90 days
- Sextant tool for designing custom molecular templates for protein-protein interaction inhibitor drug design
- Hybrid QAOA sampler that returns over 5x more samples and a broader range of pharmacophore scores compared to classical samplers